Home > Boards > US Listed > Medical - Drugs > Merck & Co. Inc. (MRK)

MRK 2018 non-GAAP EPS guidance raised to $4.30-4.36

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 722
Posts 109,279
Boards Moderated 12
Alias Born 09/05/02
160x600 placeholder
BriaCell Therapeutics Corp. to File Amendment to Management Information Circular GlobeNewswire Inc. - 10/8/2019 7:00:00 PM
Merck Cuts Emissions by 7% Dow Jones News - 10/8/2019 9:55:00 AM
Merck Issues 2018/2019 Corporate Responsibility Report Business Wire - 10/8/2019 8:00:00 AM
4D Pharma Enters Vaccine Collaboration With Merck & Co. Dow Jones News - 10/8/2019 4:55:00 AM
BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in P... GlobeNewswire Inc. - 10/7/2019 6:30:00 AM
PDS Biotechnology Shares Up 38% on Merck Collaboration Dow Jones News - 10/3/2019 10:39:00 AM
NetScientific Shares Jump as Portfolio Company PDS Collaborates With Merck & Co Dow Jones News - 10/3/2019 9:28:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 5:24:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 5:21:22 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 5:19:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 5:13:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 5:10:38 PM
Merck Gets China OK for Keytruda as Monotherapy for First-Line NSCLC Treatment Dow Jones News - 10/2/2019 8:39:00 AM
Merck Gets FDA Priority Review of Dificid in Children Dow Jones News - 10/2/2019 7:32:00 AM
Merck’s KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with A... Business Wire - 10/2/2019 6:45:00 AM
FDA Accepts Two Applications for Merck’s DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clos... Business Wire - 10/2/2019 6:30:00 AM
Merck to Hold Third-Quarter 2019 Sales and Earnings Conference Call on October 29 Business Wire - 10/1/2019 6:55:00 AM
Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month GlobeNewswire Inc. - 10/1/2019 6:30:00 AM
AstraZeneca, Merck Say Lynparza Trial Achieves Primary, Secondary Endpoints Dow Jones News - 9/30/2019 12:19:00 PM
LYNPARZA® (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Cas... Business Wire - 9/30/2019 10:30:00 AM
Merck: Phase 3 Study of Antibacterial Recarbrio Meets Key Endpoints Dow Jones News - 9/30/2019 7:39:00 AM
WebMD Health to Buy Aptus Health From Merck Dow Jones News - 9/30/2019 7:06:00 AM
Merck to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference Business Wire - 9/30/2019 6:55:00 AM
Pivotal RESTORE-IMI 2 Phase 3 Study of Merck’s RECARBRIO™ (imipenem, cilastatin, & relebactam) in Hospital-Acquired & Ven... Business Wire - 9/30/2019 6:45:00 AM
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Res... Business Wire - 9/29/2019 10:30:00 AM
DewDiligence Member Level  Thursday, 10/25/18 09:34:25 AM
Re: DewDiligence post# 392
Post # of 491 
MRK 2018 non-GAAP EPS guidance raised to $4.30-4.36 (from old range of $4.22-4.30).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist